Scolaris Content Display Scolaris Content Display

Profilaxis antimicrobiana sistémica para la gastrostomía endoscópica percutánea

Appendices

Appendix 1. Search methods used in the second review update (2011)

Electronic searches

For this second update, we searched the following databases:

  • Cochrane Wounds Group Specialised Register (searched 16 February 2011);

  • The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1);

  • Ovid MEDLINE (1950 to February Week 1 2011);

  • Ovid MEDLINE (In‐Process & Other Non‐Indexed Citations February 15, 2011);

  • Ovid EMBASE (1980 to 2011 Week 06);

  • EBSCO CINAHL (1982 to 11 February 2011)

The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in Appendix 3, Appendix 4 and Appendix 5 respectively. The Ovid MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximizing version (2008 revision); Ovid format. The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN).

The following search strategy was used in CENTRAL and adapted as appropriate for other databases:
1 MeSH descriptor Endoscopy, Gastrointestinal explode all trees
2 percutaneous
3 (#1 AND #2)
4 percutaneous NEXT endoscopic NEXT gastrostom*
5 PEG NEXT (tube* or feed*)
6 peristomal NEAR/5 endoscop*
7 (#3 OR #4 OR #5 OR #6)
8 MeSH descriptor Antibiotic Prophylaxis explode all trees
9 antimicrobial prophylaxis
10 antibiotic* NEAR/5 (prophyla* or prevent*)
11 MeSH descriptor Cephalosporins explode all trees
12 MeSH descriptor Amoxicillin‐Potassium Clavulanate Combination explode all trees
13 cefuroxine or ceftriaxone or co‐amoxiclav
14 (#8 OR #9 OR #10 OR #11 OR #12 OR #13)
15 (#7 AND #14)

There were no restrictions on the basis of language of publication, date of publication, or publication status.

Searching other resources

We searched the bibliographies of all retrieved and relevant publications identified by these strategies for further studies.

Appendix 2. Ovid MEDLINE search strategy

1 exp Endoscopy, Gastrointestinal/
2 percutaneous.tw.
3 and/1‐2
4 percutaneous endoscopic gastrostom$.tw.
5 (PEG adj (tube* or feed*)).tw.
6 (peristomal adj5 endoscop*).tw.
7 or/3‐6
8 exp Antibiotic Prophylaxis/
9 antimicrobial prophylaxis.tw.
10 (antibiotic* adj5 (prophyla* or prevent*)).tw.
11 exp Cephalosporins/
12 exp Amoxicillin‐Potassium Clavulanate Combination/
13 (cefuroxine or ceftriaxone or co‐amoxiclav).tw.
14 or/8‐13
15 7 and 14

Appendix 3. Ovid EMBASE search strategy

1 exp Percutaneous Endoscopic Gastrostomy/
2 (PEG adj (tube$ or feed$)).ti,ab.
3 (peristomal adj5 endoscop$).ti,ab.
4 or/1‐3
5 exp Antibiotic Prophylaxis/
6 antimicrobial prophylaxis.ti,ab.
7 (antibiotic$ adj5 (prophyla$ or prevent$)).ti,ab.
8 exp Cephalosporin Derivative/
9 exp Amoxicillin Plus Clavulanic Acid/
10 (cefuroxine or ceftriaxone or co‐amoxiclav).ti,ab.
11 or/5‐10
12 4 and 11

Appendix 4. EBSCO CINAHL search strategy

S15 S7 and S14
S14 S8 or S9 or S10 or S11 or S12 or S13
S13 TI ( cefuroxine or ceftriaxone or co‐amoxiclav ) or AB ( cefuroxine or ceftriaxone or co‐amoxiclav )
S12 (MH "Amoxicillin")
S11 (MH "Cephalosporins+")
S10 TI ( antibiotic* N5 prophylaxis or antibiotic* N5 prevent* ) or AB ( antibiotic* N5 prophylaxis or antibiotic* N5 prevent* )
S9TI antimicrobial prophylaxis or AB antimicrobial prophylaxis
S8 (MH "Antibiotic Prophylaxis")
S7 S3 or S4 or S5 or S6
S6 TI peristom* N3 endoscop* or AB peristom* N3 endoscop*
S5 TI (PEG N3 tube* or PEG N3 feed* ) or AB (PEG N3 tube* or PEG N3 feed*)
S4 TI percutaneous endoscopic gastrostom* or AB percutaneous endoscopic gastrostom*
S3 S1 and S2
S2 TI percutaneous or AB percutaneous
S1 (MH "Endoscopy, Gastrointestinal+")

Appendix 5. Risk of bias definitions

1. Was the allocation sequence randomly generated?

Low risk of bias

The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.

High risk of bias

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.

Unclear

Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.

2. Was the treatment allocation adequately concealed?

Low risk of bias

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially‐numbered drug containers of identical appearance; sequentially‐numbered, opaque, sealed envelopes.

High risk of bias

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear

Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

3. Blinding ‐ was knowledge of the allocated interventions adequately prevented during the study?

Low risk of bias

Any one of the following.

  • No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.

  • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non‐blinding of others unlikely to introduce bias.

High risk of bias

Any one of the following.

  • No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.

  • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, and the non‐blinding of others likely to introduce bias.

Unclear

Any one of the following.

  • Insufficient information to permit judgement of low or high risk of bias.

  • The study did not address this outcome.

4. Were incomplete outcome data adequately addressed?

Low risk of bias

Any one of the following.

  • No missing outcome data.

  • Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).

  • Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size.

  • Missing data have been imputed using appropriate methods.

High risk of bias

Any one of the following.

  • Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size.

  • ‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.

  • Potentially inappropriate application of simple imputation.

Unclear

Any one of the following.

  • Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).

  • The study did not address this outcome.

5. Are reports of the study free of suggestion of selective outcome reporting?

Low risk of bias

Any of the following.

  • The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way.

  • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon)

High risk of bias

Any one of the following.

  • Not all of the study’s pre‐specified primary outcomes have been reported.

  • One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified.

  • One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).

  • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis.

  • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear

Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

6. Other sources of potential bias

Low risk of bias

The study appears to be free of other sources of bias.

High risk of bias

There is at least one important risk of bias. For example, the study:

  • had a potential source of bias related to the specific study design used; or

  • has been claimed to have been fraudulent; or

  • had some other problem.

Unclear

There may be a risk of bias, but there is either:

  • insufficient information to assess whether an important risk of bias exists; or

  • insufficient rationale or evidence that an identified problem will introduce bias.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Comparison 1 Systemic antibiotic (IV) compared with placebo, Outcome 1 Peristomal infection.
Figuras y tablas -
Analysis 1.1

Comparison 1 Systemic antibiotic (IV) compared with placebo, Outcome 1 Peristomal infection.

Comparison 2 Systemic antibiotic (IV) compared with no intervention, Outcome 1 Peristomal infection.
Figuras y tablas -
Analysis 2.1

Comparison 2 Systemic antibiotic (IV) compared with no intervention, Outcome 1 Peristomal infection.

Comparison 3 Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic, Outcome 1 Peristomal infection.
Figuras y tablas -
Analysis 3.1

Comparison 3 Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic, Outcome 1 Peristomal infection.

Comparison 3 Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic, Outcome 2 Allocation concealment.
Figuras y tablas -
Analysis 3.2

Comparison 3 Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic, Outcome 2 Allocation concealment.

Comparison 3 Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic, Outcome 3 Sponsorship.
Figuras y tablas -
Analysis 3.3

Comparison 3 Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic, Outcome 3 Sponsorship.

Comparison 4 Systemic antibiotic compared with systemic antibiotic, Outcome 1 Systemic antibiotic (IV) compared with systemic antibiotic (IV).
Figuras y tablas -
Analysis 4.1

Comparison 4 Systemic antibiotic compared with systemic antibiotic, Outcome 1 Systemic antibiotic (IV) compared with systemic antibiotic (IV).

Comparison 4 Systemic antibiotic compared with systemic antibiotic, Outcome 2 Systemic antibiotic (PEG) compared with systemic antibiotic (IV).
Figuras y tablas -
Analysis 4.2

Comparison 4 Systemic antibiotic compared with systemic antibiotic, Outcome 2 Systemic antibiotic (PEG) compared with systemic antibiotic (IV).

Comparison 5 Systemic antibiotic (IV) compared with systemic antibiotic (IV) and skin antiseptic, Outcome 1 Peristomal infection.
Figuras y tablas -
Analysis 5.1

Comparison 5 Systemic antibiotic (IV) compared with systemic antibiotic (IV) and skin antiseptic, Outcome 1 Peristomal infection.

Comparison 6 Skin antiseptic compared with systemic antibiotic (IV) and skin antiseptic, Outcome 1 Peristomal infection.
Figuras y tablas -
Analysis 6.1

Comparison 6 Skin antiseptic compared with systemic antibiotic (IV) and skin antiseptic, Outcome 1 Peristomal infection.

Comparison 1. Systemic antibiotic (IV) compared with placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peristomal infection Show forest plot

8

586

Odds Ratio (M‐H, Fixed, 95% CI)

0.34 [0.22, 0.53]

Figuras y tablas -
Comparison 1. Systemic antibiotic (IV) compared with placebo
Comparison 2. Systemic antibiotic (IV) compared with no intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peristomal infection Show forest plot

3

623

Odds Ratio (M‐H, Fixed, 95% CI)

0.30 [0.17, 0.53]

Figuras y tablas -
Comparison 2. Systemic antibiotic (IV) compared with no intervention
Comparison 3. Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peristomal infection Show forest plot

12

1271

Odds Ratio (M‐H, Fixed, 95% CI)

0.36 [0.26, 0.50]

2 Allocation concealment Show forest plot

12

1271

Odds Ratio (M‐H, Fixed, 95% CI)

0.47 [0.34, 0.65]

2.1 adequate allocation concealment

8

554

Odds Ratio (M‐H, Fixed, 95% CI)

0.58 [0.38, 0.88]

2.2 unclear/inadequate concealment

4

717

Odds Ratio (M‐H, Fixed, 95% CI)

0.34 [0.21, 0.58]

3 Sponsorship Show forest plot

12

1271

Odds Ratio (M‐H, Fixed, 95% CI)

0.36 [0.26, 0.50]

3.1 Trials with no sponsorship

10

962

Odds Ratio (M‐H, Fixed, 95% CI)

0.38 [0.25, 0.56]

3.2 Trials with sponsorship

2

309

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.18, 0.58]

Figuras y tablas -
Comparison 3. Systemic antibiotic (IV) compared with placebo/no intervention/skin antiseptic
Comparison 4. Systemic antibiotic compared with systemic antibiotic

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Systemic antibiotic (IV) compared with systemic antibiotic (IV) Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

1.1 Peristomal infection

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Systemic antibiotic (PEG) compared with systemic antibiotic (IV) Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 4. Systemic antibiotic compared with systemic antibiotic
Comparison 5. Systemic antibiotic (IV) compared with systemic antibiotic (IV) and skin antiseptic

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peristomal infection Show forest plot

1

68

Odds Ratio (M‐H, Fixed, 95% CI)

15.78 [1.90, 130.86]

Figuras y tablas -
Comparison 5. Systemic antibiotic (IV) compared with systemic antibiotic (IV) and skin antiseptic
Comparison 6. Skin antiseptic compared with systemic antibiotic (IV) and skin antiseptic

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peristomal infection Show forest plot

1

62

Odds Ratio (M‐H, Fixed, 95% CI)

15.63 [1.84, 133.09]

Figuras y tablas -
Comparison 6. Skin antiseptic compared with systemic antibiotic (IV) and skin antiseptic